---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-24-000099"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:12:21.522699+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Keros reports elritercept Phase 2 data: 134.1 wk median TI in MDS; spleen reductions in MF

## Summary
- 55.2% (48/87) of mITT patients achieved overall erythroid response; median TI duration 134.1 weeks in lower-risk MDS.
- 31.4% (16/51) of high-transfusion-burden MDS patients achieved TI >=8 weeks; 50% of those had TI >=24 weeks.
- In MF, 63.4% (26/41) of transfusion-dependent patients had reduced RBC burden; 24.4% achieved TI.
- 40% (8/20) of MF patients with baseline spleen >=450 cm³ had spleen volume reduction at week 24; 3 had >=35% reduction.
- Elritercept generally well-tolerated; Phase 3 RENEW trial in MDS expected to begin enrollment soon.

## SEC filing metadata
- accession: 0001664710-24-000099
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000099/0001664710-24-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000099/kros-20241209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-24-000099
- JSON: https://secwatch.observer/filing/0001664710-24-000099.json
- Plain text: https://secwatch.observer/filing/0001664710-24-000099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.